Lipoclin (clinofibrate) / Sumitomo Pharma - LARVOL DELTA

Clinofibrate Disrupts the SNORA80B/YTHDC1-Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC. (PubMed, Adv Sci (Weinh)) - "The repurposing of clinofibrate demonstrates the therapeutic potential of targeting snoRNA-mediated pathways, providing both mechanistic insights and a clinically translatable strategy for ESCC treatment. These findings redefine the functional scope of snoRNAs in cancer pathogenesis."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • YTHDC1